KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Non Operating Income (2021 - 2025)

Historic Non Operating Income for Xenon Pharmaceuticals (XENE) over the last 5 years, with Q3 2025 value amounting to $6.1 million.

  • Xenon Pharmaceuticals' Non Operating Income fell 4210.68% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.1 million, marking a year-over-year decrease of 2544.5%. This contributed to the annual value of $40.9 million for FY2024, which is 3031.66% up from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Non Operating Income stood at $6.1 million for Q3 2025, which was down 4210.68% from $8.9 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year Non Operating Income high stood at $11.5 million for Q1 2024, and its period low was -$2.7 million during Q1 2022.
  • Its 5-year average for Non Operating Income is $5.8 million, with a median of $7.6 million in 2023.
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Non Operating Income soared by 302355.37% in 2022, and later crashed by 4210.68% in 2025.
  • Quarter analysis of 5 years shows Xenon Pharmaceuticals' Non Operating Income stood at -$242000.0 in 2021, then soared by 3023.55% to $7.1 million in 2022, then increased by 23.63% to $8.7 million in 2023, then dropped by 9.18% to $7.9 million in 2024, then decreased by 23.0% to $6.1 million in 2025.
  • Its Non Operating Income stands at $6.1 million for Q3 2025, versus $8.9 million for Q2 2025 and $8.1 million for Q1 2025.